Clinical Trial

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Study acronym: ARCHED
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be randomised to receive either R-miniCHOP alone or R-miniCHOP with Acalabrutinib.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-04-19; most recent amendment 2026-06-24.
Status change: Not Yet Recruiting → Recruiting 2023-05-09
Trial Details
NCT Number NCT05820841
Lead Sponsor Universität des Saarlandes
Collaborators: University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital Giessen and Marburg, Saarland University Medical Center, AstraZeneca
Conditions Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Enrollment 330 participants
Start Date 2023-06-07
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-29